Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type-B receptor function within pulmonary endothelial cells. Spironolactone has demonstrated...
Enregistré dans:
Auteurs principaux: | Zeenat Safdar, Eunah Cho |
---|---|
Format: | article |
Langue: | EN |
Publié: |
SAGE Publishing
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/feae43b6f1f849f2a33c67f2dc06260f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Liver abnormalities in pulmonary arterial hypertension
par: Nils P. Nickel, et autres
Publié: (2021) -
Systemic arterial properties in pulmonary hypertension
par: Randi Goodman, et autres
Publié: (2021) -
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
par: Micheal C. McInnis, et autres
Publié: (2021) -
PeakPCO combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
par: Ci-Jun Luo, et autres
Publié: (2021) -
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
par: Robert P. Frantz, et autres
Publié: (2021)